Pharmaids Pharmaceuticals (524572) Q4 25/26 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, were approved, with unmodified audit opinions from statutory auditors.

• The group operates in a single segment: Contract Research and Manufacturing Services.

• A corporate guarantee of up to Rs. 75 lakhs was approved for a material subsidiary under the Emergency Credit Line Guarantee Scheme (ECLGS) 5.0.

Financial highlights

• Standalone revenue from operations for FY26 was Rs. 1,060.25 lakhs, up from Rs. 234.09 lakhs in FY25; consolidated revenue was Rs. 2,788.24 lakhs, up from Rs. 1,944.74 lakhs year-over-year.

• Standalone net loss for FY26 was Rs. (1,043.72) lakhs, compared to Rs. (727.92) lakhs in FY25; consolidated net loss was Rs. (1,157.19) lakhs, compared to Rs. (1,350.51) lakhs in FY25.

• Standalone EPS for FY26 was Rs. (2.95) vs. Rs. (2.06) in FY25; consolidated EPS was Rs. (3.31) vs. Rs. (3.05) in FY25.

• Total standalone assets as of March 31, 2026, were Rs. 8,396.00 lakhs; consolidated assets were Rs. 8,726.21 lakhs.

Outlook and guidance

• No explicit forward-looking guidance provided; management continues to focus on contract research and manufacturing services.